We value Dabur at 50x FY23E EPS at a discount to its 3 year avg. PE of 53x given its market leadership in Ayurvedic category, rich legacy, fearlessness in NPD launches, healthy margins and operating cash flows. We initiate coverage with a BUY rating and TP of Rs. 610/share.